Answers are grounded in this paper and cite their sources.
We report 2 patients with chronic myeloid leukemia in the chronic phase showing diffusely increased F-18 fluorodeoxyglucose (FDG) uptake in the bone marrow before treatment. Follow-up FDG positron emission tomography (PET) scans were performed in a patient after cessation of treatment and in the other under treatment. Both FDG PET findings showed reduced FDG uptake in the bone marrow. A series of these FDG PET findings suggest the usefulness of FDG PET for the diagnosis and monitoring of chronic myeloid leukemia after treatment.
No takes yet. Share an insight, caveat, or question.
Nakajo et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: